Lanreotide
Lanreotide, Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Lanreotide, Somatuline depot
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lanreotide acetate | ANDA | 2025-02-01 |
| somatuline depot | New Drug Application | 2024-10-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neuroendocrine tumors | EFO_1001901 | D018358 | D3A.8 |
| acromegaly | — | D000172 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LANREOTIDE ACETATE, SOMATULINE DEPOT, IPSEN PHARMA | |||
| 2024-09-15 | ODE-156 | ||
Patent Expiration
No data
Clinical
Clinical Trials
116 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | — | — | 1 | 3 | 8 | 3 | 12 | 25 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 6 | 3 | 2 | 12 | 23 |
| Carcinoid tumor | D002276 | — | D3A.00 | — | 2 | 2 | 1 | 1 | 6 |
| Circulating neoplastic cells | D009360 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | 1 | — | 2 | 5 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | 1 | — | 2 | 4 |
| Intestinal neoplasms | D007414 | — | C26.0 | 1 | 1 | 1 | — | 2 | 4 |
| Malignant carcinoid syndrome | D008303 | — | E34.0 | — | — | 3 | — | 1 | 4 |
| Serotonin syndrome | D020230 | EFO_1001842 | G90.81 | — | — | 3 | — | 1 | 4 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 3 | 3 | — | 1 | 4 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 3 | 3 | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | — | 2 | 1 | — | — | 3 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | 1 | 3 |
| Intestinal obstruction | D007415 | — | K56.60 | — | 2 | 1 | — | — | 3 |
Show 15 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dumping syndrome | D004377 | EFO_1001307 | K91.1 | — | 1 | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
| Digestive system neoplasms | D004067 | — | — | — | 1 | — | — | — | 1 |
| Pheochromocytoma | D010673 | — | — | — | 1 | — | — | — | 1 |
| Paraganglioma | D010235 | — | — | — | 1 | — | — | — | 1 |
| Intestinal diseases | D007410 | — | K63.9 | — | 1 | — | — | — | 1 |
| Gastrointestinal motility | D005769 | — | — | — | 1 | — | — | — | 1 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 1 | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | — | — | — | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lanreotide |
| INN | lanreotide |
| Description | LANREOTIDE |
| Classification | Peptide |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 108736-35-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201185 |
| ChEBI ID | — |
| PubChem CID | 71349 |
| DrugBank | DB06791 |
| UNII ID | 0G3DE8943Y (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,023 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,402 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use